BRPI1004900A2 - pró-fármaco, uso de uma estrutura parcial, método para introduzir um medicamento, método para tratar um paciente, uso de um pró-fármaco e método para produção de uma guanidina n - alcoxi - Google Patents

pró-fármaco, uso de uma estrutura parcial, método para introduzir um medicamento, método para tratar um paciente, uso de um pró-fármaco e método para produção de uma guanidina n - alcoxi

Info

Publication number
BRPI1004900A2
BRPI1004900A2 BRPI1004900A BRPI1004900A BRPI1004900A2 BR PI1004900 A2 BRPI1004900 A2 BR PI1004900A2 BR PI1004900 A BRPI1004900 A BR PI1004900A BR PI1004900 A BRPI1004900 A BR PI1004900A BR PI1004900 A2 BRPI1004900 A2 BR PI1004900A2
Authority
BR
Brazil
Prior art keywords
prodrug
drug
introducing
patient
treating
Prior art date
Application number
BRPI1004900A
Other languages
English (en)
Inventor
Bernd Clement
Dennis Schade
Original Assignee
Dritte Patentportfolio Beteiligungs Gmbh & Co Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dritte Patentportfolio Beteiligungs Gmbh & Co Kg filed Critical Dritte Patentportfolio Beteiligungs Gmbh & Co Kg
Publication of BRPI1004900A2 publication Critical patent/BRPI1004900A2/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C257/00Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines
    • C07C257/10Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. amidines
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C279/00Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
    • C07C279/18Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to carbon atoms of six-membered aromatic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/155Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/16Antivirals for RNA viruses for influenza or rhinoviruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • A61P33/02Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/02Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C257/00Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines
    • C07C257/10Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. amidines
    • C07C257/18Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. amidines having carbon atoms of amidino groups bound to carbon atoms of six-membered aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C259/00Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups
    • C07C259/12Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. N-hydroxyamidines
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D309/00Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/16Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D309/28Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • AIDS & HIV (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyrane Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
BRPI1004900A 2009-01-09 2010-01-08 pró-fármaco, uso de uma estrutura parcial, método para introduzir um medicamento, método para tratar um paciente, uso de um pró-fármaco e método para produção de uma guanidina n - alcoxi BRPI1004900A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102009004204A DE102009004204A1 (de) 2009-01-09 2009-01-09 Verfahren zur verbesserten Bioaktivierung von Arzneistoffen
PCT/DE2010/000009 WO2010078867A1 (de) 2009-01-09 2010-01-08 Verfahren zur verbesserten bioaktivierung von arzneistoffen

Publications (1)

Publication Number Publication Date
BRPI1004900A2 true BRPI1004900A2 (pt) 2016-04-05

Family

ID=42049535

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI1004900A BRPI1004900A2 (pt) 2009-01-09 2010-01-08 pró-fármaco, uso de uma estrutura parcial, método para introduzir um medicamento, método para tratar um paciente, uso de um pró-fármaco e método para produção de uma guanidina n - alcoxi

Country Status (13)

Country Link
US (1) US20120077876A1 (pt)
EP (1) EP2376074B1 (pt)
JP (1) JP5918538B2 (pt)
KR (3) KR20110102506A (pt)
CN (1) CN102378628A (pt)
AU (1) AU2010204395B2 (pt)
BR (1) BRPI1004900A2 (pt)
CA (1) CA2749009A1 (pt)
DE (1) DE102009004204A1 (pt)
IL (1) IL213955A (pt)
RU (1) RU2550969C2 (pt)
SG (2) SG172911A1 (pt)
WO (1) WO2010078867A1 (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2550966T3 (pl) * 2011-07-25 2017-03-31 Dritte Patentportfolio Beteiligungsgesellschaft Mbh & Co. Kg Estry kwasu amidooksymokarboksylowego dabigatranu jako proleki i ich zastosowanie jako lek
US20230097988A1 (en) * 2020-02-26 2023-03-30 Pam Theragnostics Gmbh Methods for determining peptidylglycine alpha-amidating monooxygenase (pam) and its use for diagnostic purpose
CN120476119A (zh) 2022-10-27 2025-08-12 先正达农作物保护股份公司 杀微生物的杂双环二氢噁二嗪衍生物
JP2026502124A (ja) 2022-12-19 2026-01-21 シンジェンタ クロップ プロテクション アクチェンゲゼルシャフト 殺微生物性ピリダジンジヒドロオキサジアジン誘導体
WO2024132895A1 (en) 2022-12-19 2024-06-27 Syngenta Crop Protection Ag Microbiocidal dihydrooxadiazinyl pyridazinone compounds

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1080234A (en) * 1975-09-11 1980-06-24 Daniel Farge Derivatives of amidoximes
DE3431916A1 (de) * 1984-08-30 1986-03-13 Bayer Ag, 5090 Leverkusen Fluoralkoxyphenylsulfonylguanidine
DE3516616A1 (de) * 1984-08-30 1986-03-13 Bayer Ag, 5090 Leverkusen Benzodisultame
JPH02295961A (ja) * 1989-05-09 1990-12-06 Nippon Soda Co Ltd グアニジン誘導体及びその製造方法及び殺虫・殺ダニ剤
FR2678938B1 (fr) * 1991-07-10 1993-10-08 Rhone Poulenc Rorer Sa Derives de pyrrolidine, leur preparation et les medicaments les contenant.
US5587372A (en) * 1991-12-12 1996-12-24 Roussel Uclaf Cephalosporins
US5225408A (en) * 1991-12-20 1993-07-06 E. R. Squibb & Sons, Inc. Biphenyl oxadiazinone angiotensin II inhibitors
DE4321444A1 (de) 1993-06-28 1995-01-05 Bernd Prof Dr Clement Pharmazeutische Zubereitung
US5723495A (en) * 1995-11-16 1998-03-03 The University Of North Carolina At Chapel Hill Benzamidoxime prodrugs as antipneumocystic agents
TWI238827B (en) * 1995-12-21 2005-09-01 Astrazeneca Ab Prodrugs of thrombin inhibitors
US5840758A (en) * 1996-06-06 1998-11-24 Abbott Laboratories Oxime derivatives of fenamates as inhibitors of prostaglandin biosynthesis
ES2282127T3 (es) * 1999-07-08 2007-10-16 University Of North Carolina At Chapel Hill Nuevos profarmacos para amidinas anticrobianas.
WO2003053917A1 (en) * 2001-12-21 2003-07-03 Nippon Soda Co.,Ltd. Guanidine compounds and pest controllers
ZA200703912B (en) * 2004-10-20 2008-09-25 Serono Lab 3-arylamino pyridine derivatives
US7875602B2 (en) * 2005-10-21 2011-01-25 Sutter West Bay Hospitals Camptothecin derivatives as chemoradiosensitizing agents
CN101454299A (zh) * 2006-03-27 2009-06-10 东丽株式会社 酰脲衍生物及其医药用途
DE102006034256A1 (de) * 2006-07-21 2008-01-31 Christian-Albrechts-Universität Zu Kiel Verbesserung der Bioverfügbarkeit von Wirkstoffen mit Amidinfunktion in Arzneimitteln
DE102008005484A1 (de) * 2008-01-22 2009-07-23 Schaper, Wolfgang, Dr. Induktion und Förderung der Arteriogenese
DE102008007440A1 (de) * 2008-02-01 2009-08-13 Dritte Patentportfolio Beteiligungsgesellschaft Mbh & Co.Kg Aminosäurederivate als Arzneistoffe
DE102008007381A1 (de) * 2008-02-01 2009-08-13 Dritte Patentportfolio Beteiligungsgesellschaft Mbh & Co.Kg Amidine und Guanidine und deren Derivate zur Behandlung von Krankheiten

Also Published As

Publication number Publication date
KR20150015002A (ko) 2015-02-09
JP5918538B2 (ja) 2016-05-18
RU2011133233A (ru) 2013-02-20
JP2012514608A (ja) 2012-06-28
IL213955A0 (en) 2011-08-31
WO2010078867A1 (de) 2010-07-15
CN102378628A (zh) 2012-03-14
IL213955A (en) 2016-12-29
KR20160042140A (ko) 2016-04-18
RU2550969C2 (ru) 2015-05-20
SG172911A1 (en) 2011-08-29
DE102009004204A1 (de) 2010-07-15
US20120077876A1 (en) 2012-03-29
AU2010204395A1 (en) 2011-09-01
CA2749009A1 (en) 2010-07-15
AU2010204395B2 (en) 2016-04-14
EP2376074B1 (de) 2019-03-13
EP2376074A1 (de) 2011-10-19
SG10201504075YA (en) 2015-06-29
KR20110102506A (ko) 2011-09-16

Similar Documents

Publication Publication Date Title
BRPI1012116A2 (pt) composição farmacêutica para o tratamento de doenças cardíacas
BRPI1015983A2 (pt) composto, uso do composto, método para tratar um paciente, e, composição farmacêutica.
PT2280973E (pt) Análogos de carba-nucleósido para tratamento antiviral
BRPI1010937A2 (pt) composto, uso de um composto, e, método para tratar câncer
BRPI0817423A2 (pt) Processos para a preparação de um composto, para a preparação de uma formulação farmacêutica, e para a preparação de um intermediário de um composto, e, composto
BR112014011671A2 (pt) composto, composição farmacêutica, método para o tratamento de uma doença ou condição, e, uso de um composto
BRPI0820474A2 (pt) método de tratamento de uma doença, uso de composto, e, composto
BRPI0813192A2 (pt) composto para a regeneração de tecidos e método de preparação de um composto para a regeneração de tecidos
BRPI1010775A2 (pt) composição, método para preparar uma composição, e, uso de uma composição.
EP2538988A4 (en) METHOD FOR TISSUE-DECELULARIZATION
BRPI0812851A2 (pt) Composto, composição farmacêutica, métodos para o tratamento de uma doença e de uma condição em um indivíduo, processo para preparar um composto, e, uso de um composto
BR112012022878A2 (pt) composto, composição farmacêutica, uso do compostos e método de tratamento
BR112014010460A2 (pt) composto, composição farmacêutica, processo para produzir uma composição farmacêutica, método de tratamento, kit e uso de uma composição farmacêutica
BR112013020804A2 (pt) rede inflável e método para posicionamento de paciente
BR112014008126A2 (pt) composto, método para o tratamento, composição farmacêutica, utilização de um composto e invenção
BR112012026570A2 (pt) composto, composição farmacêutica, uso de um composto, método para o tratamento de um indíviduo e produto combinado
BR112012026843A2 (pt) composição, composição farmacêutica, processo para preparar uma composição farmacêutica, uso de uma composição e método para tratamento de hiv
DK2222272T3 (da) Behandling af luftvejssygdom
BR112012001998A2 (pt) solução oftálmica, uso de um composto, e, método para preparação de uma solução oftálmica.
BRPI0911685A2 (pt) composto, método para o tratamento de uma doença, uso de um composto, composição farmacêutica, e, kit
BR112012000502A2 (pt) terapia de combinação para o tratamento de diabetes
BRPI0912539A2 (pt) composto, composição farmacêutica , método para tratar uma doença, e, uso do composto.
BR112012003280A2 (pt) composição farmacêutica para administração oral, método para tratar uma doença, uso do composto, e, composto.
BRPI1012979A2 (pt) composição para cuidado oral, método para preparar a mesma, e, uso de um composto
BRPI0811844A2 (pt) Composto, e, método para tratar um paciente

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]